Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 6
2005 1
2006 4
2007 6
2008 10
2009 10
2010 17
2011 18
2012 22
2013 22
2014 22
2015 33
2016 15
2017 18
2018 27
2019 25
2020 33
2021 31
2022 40
2023 42
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

389 results

Results by year

Filters applied: . Clear all
Page 1
Bas les masques, et après ?
Kaiser L, Vetter P, Calmy A, Manuel O, Calandra T. Kaiser L, et al. Among authors: calmy a. Rev Med Suisse. 2022 Apr 13;18(777):691-692. doi: 10.53738/REVMED.2022.18.777.691. Rev Med Suisse. 2022. PMID: 35417096 French. No abstract available.
Mpox in people with advanced HIV infection: a global case series.
Mitjà O, Alemany A, Marks M, Lezama Mora JI, Rodríguez-Aldama JC, Torres Silva MS, Corral Herrera EA, Crabtree-Ramirez B, Blanco JL, Girometti N, Mazzotta V, Hazra A, Silva M, Montenegro-Idrogo JJ, Gebo K, Ghosn J, Peña Vázquez MF, Matos Prado E, Unigwe U, Villar-García J, Wald-Dickler N, Zucker J, Paredes R, Calmy A, Waters L, Galvan-Casas C, Walmsley S, Orkin CM; SHARE-NET writing group. Mitjà O, et al. Among authors: calmy a. Lancet. 2023 Mar 18;401(10380):939-949. doi: 10.1016/S0140-6736(23)00273-8. Epub 2023 Feb 21. Lancet. 2023. PMID: 36828001
[Antiretroviral therapy].
von Braun A, Furrer H, Battegay M, Calmy A, Cavassini M, Vernazza P, Bernasconi E, Weber R, Günthard HF. von Braun A, et al. Among authors: calmy a. Ther Umsch. 2014 Aug;71(8):461-8. doi: 10.1024/0040-5930/a000538. Ther Umsch. 2014. PMID: 25093310 Review. German.
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. Cahn P, et al. Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Lancet. 2019. PMID: 30420123 Clinical Trial.
Use of Ritonavir-Boosted Nirmatrelvir in Pregnancy.
Siberry GK, Mofenson LM, Calmy A, Reddy UM, Abrams EJ. Siberry GK, et al. Among authors: calmy a. Clin Infect Dis. 2022 Dec 19;75(12):2279-2281. doi: 10.1093/cid/ciac666. Clin Infect Dis. 2022. PMID: 35975658 No abstract available.
A Case of Mpox Reinfection.
Musumeci S, Najjar I, Amari EBE, Schibler M, Jacquerioz F, Yerly S, Renzoni A, Calmy A, Kaiser L. Musumeci S, et al. Among authors: calmy a. Clin Infect Dis. 2023 Jul 5;77(1):135-137. doi: 10.1093/cid/ciad147. Clin Infect Dis. 2023. PMID: 36905148 Free PMC article.
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.
Ambrosioni J, Levi L, Alagaratnam J, Van Bremen K, Mastrangelo A, Waalewijn H, Molina JM, Guaraldi G, Winston A, Boesecke C, Cinque P, Bamford A, Calmy A, Marzolini C, Martínez E, Oprea C, Welch S, Koval A, Mendao L, Rockstroh JK; EACS Governing Board. Ambrosioni J, et al. Among authors: calmy a. HIV Med. 2023 Nov;24(11):1126-1136. doi: 10.1111/hiv.13542. Epub 2023 Oct 18. HIV Med. 2023. PMID: 37849432
HIV and antiretroviral therapy-related fat alterations.
Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, Brown TT, Capeau J. Koethe JR, et al. Among authors: calmy a. Nat Rev Dis Primers. 2020 Jun 18;6(1):48. doi: 10.1038/s41572-020-0181-1. Nat Rev Dis Primers. 2020. PMID: 32555389 Review.
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.
Trøseid M, Arribas JR, Assoumou L, Holten AR, Poissy J, Terzić V, Mazzaferri F, Baño JR, Eustace J, Hites M, Joannidis M, Paiva JA, Reuter J, Püntmann I, Patrick-Brown TDJH, Westerheim E, Nezvalova-Henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Péterfi Z, Tsiodras S, Rezek M, Briel M, Ünal S, Schlegel M, Ader F, Lacombe K, Amdal CD, Rodrigues S, Tonby K, Gaudet A, Heggelund L, Mootien J, Johannessen A, Møller JH, Pollan BD, Tveita AA, Kildal AB, Richard JC, Dalgard O, Simensen VC, Baldé A, de Gastines L, Del Álamo M, Aydin B, Lund-Johansen F, Trabaud MA, Diallo A, Halvorsen B, Røttingen JA, Tacconelli E, Yazdanpanah Y, Olsen IC, Costagliola D; EU SolidAct study group. Trøseid M, et al. Crit Care. 2023 Jan 10;27(1):9. doi: 10.1186/s13054-022-04205-8. Crit Care. 2023. PMID: 36627655 Free PMC article. Clinical Trial.
389 results